---
title: Oral Infigratinib Therapy in Children with Achondroplasia
date: '2024-11-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39555818/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241119173555&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: The administration of oral infigratinib did not result
  in any apparent major safety signal and increased the annualized height velocity
  and z score and decreased the upper-to-lower body segment ratio at 18 months of
  treatment in cohort 5. (Funded by BridgeBio Pharma; PROPEL2 ClinicalTrials.gov number,
  ...'
disable_comments: true
---
CONCLUSIONS: The administration of oral infigratinib did not result in any apparent major safety signal and increased the annualized height velocity and z score and decreased the upper-to-lower body segment ratio at 18 months of treatment in cohort 5. (Funded by BridgeBio Pharma; PROPEL2 ClinicalTrials.gov number, ...